Cancer Vaccine Clinical Trials in China: Evidence and Enrollment Conditions
Clinical Trials & Advanced Therapies
Cancer vaccines are among the most frequently misrepresented categories in medical travel enquiries. Patients hear "vaccine" and expect prevention or a gentle alternative to chemotherapy; trials in fact enrol specific stages, require specific biomarkers and often combine the vaccine with standard treatment rather than replacing it.
What these trials actually test
- Neoantigen vaccines, personalised to a patient's tumour sequencing results
- Shared-antigen vaccines against defined targets such as HPV-related cancers
- Dendritic cell vaccines, prepared from the patient's own cells
- Combinations with checkpoint inhibitors, where the vaccine is intended to increase response rate
Enrolment conditions in practice
Most protocols require measurable disease, a defined line of prior therapy, adequate organ function and — for personalised vaccines — sufficient tumour tissue for sequencing, which can mean a fresh biopsy. Production of a personalised vaccine takes weeks, so timing between apheresis or biopsy and first dose is part of the protocol, not an afterthought.
Evidence, honestly stated
Some shared-antigen vaccines have shown benefit in specific settings; many personalised approaches remain experimental with response evaluated by immune and imaging endpoints. A trial is not a promise of efficacy. Ask what the primary endpoint is, whether the study is randomised, and what has been published from earlier phases of the same product.
Questions for the trial team
- Is the vaccine given with standard therapy, or instead of it?
- How much tissue is needed, and can an existing block be used?
- What is the time from screening to first dose?
- What happens at the end of the protocol if the disease is stable?
Next step: send the pathology report and sequencing results if available, and we will identify which vaccine trials could plausibly accept this case.
